← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Hillhurst Biopharmaceuticals, Inc.
Montrose, CA
$14,894,056
Total funding
14
Grants
Funding over time
peak $3M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,894,056 · 14
By mechanism
R44$8,380,993 · 3
R41$2,449,606 · 6
UG3$2,111,258 · 1
R43$1,224,088 · 3
UH3$728,111 · 1
Investigators at Hillhurst Biopharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease$2,111,258
UG3 · FY2022 · NS
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$1,270,298
R44 · FY2018 · HL
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$999,898
R44 · FY2024 · HL
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$999,718
R44 · FY2025 · HL
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$999,578
R44 · FY2023 · HL
HBI-002 to Treat Diabetic Retinopathy$961,240
R44 · FY2025 · EY
HBI-002 to Treat Diabetic Retinopathy$950,200
R44 · FY2024 · EY
HBI-002 to Treat Delayed Graft Function in Kidney Transplant$862,618
R44 · FY2016 · DK
Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease$728,111
UH3 · FY2024 · NS
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$702,410
R44 · FY2019 · HL
HBI-002 to Treat Delayed Graft Function in Kidney Transplant$635,033
R44 · FY2017 · DK
Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke$475,519
R43 · FY2015 · NS
HBI-002 to Treat Parkinsonâs Disease$453,158
R41 · FY2021 · NS
HBI-002 for Cystic Fibrosis$299,975
R41 · FY2024 · HL
HBI-002 to Treat Diabetic Retinopathy$299,899
R41 · FY2021 · EY
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury$299,894
R41 · FY2023 · AI
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury$299,894
R41 · FY2022 · AI
Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$258,257
R43 · FY2016 · HL
Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke$223,821
R43 · FY2016 · NS
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity$222,338
R41 · FY2020 · HL